

R&D Day 2023: At a Glance

On September 14, during its R&D Day, BMS detailed:

<p>Robust pipeline supporting long-term, sustainable growth</p>	<p>Differentiated research platforms, including Cell Therapy and Targeted Protein Degradation</p>	<p>Objectives to further enhance R&D productivity</p>
--	--	--

Advancing a Promising Pipeline

<p>12 Registrational assets expected to double from 6 to 12 over next 18 months</p>	<p>25+ Indication expansion opportunities</p>	<p>9 high-potential early assets to watch</p>
--	--	--

Strengthening Scientific Leadership

In registrational studies

mezigdomide	reprotrectinib
iderdomide	cendakimab
milvexian	LPA ₁ antagonist

Registrational studies pending

CD19 NEX T	BET Inhibitor (BMS-986158)
GPC5D CAR T	alnuctamab
golcadomide	AR LDD

Harnessing Differentiated Research Platforms




Cell Therapy

- Expanding manufacturing capacity
- Advancing next generation assets and innovative technologies (e.g. allogenic and dual-targeting CARs)
- Moving rapidly into immunologic disease

Targeted Protein Degradation

- Advancing clinical and pre-clinical pipeline with an expansive library of assets
- 3 registrational assets with 4 more clinical and 15 pre clinical
- Potential across several diseases
- Positioned to deliver ~4 investigational new drugs (INDs) each year

Enhancing R&D Productivity

-  **Increase & Sustain INDs** Deliver approximately **10 INDs** per year
-  **Probability of Success** Increasing success rates from first-in-human to approval to **~20%**
-  **Reduce Cycle Times** Achieve median of **~6.5 years** from first-in-human to approval